ITM and SpiroChem Enter Strategic Collaboration to Advance Novel Radiopharmaceutical Development

en.Wedoany.com Reported - Garching/Munich, Germany and Basel, Switzerland, September 8, 2026 – Radiopharmaceutical biotechnology company ITM Isotope Technologies Munich SE and Swiss collaborative research organization SpiroChem AG today announced a strategic drug discovery collaboration focused on a novel radiopharmaceutical candidate from ITM's pipeline. The specific target and financial terms of the collaboration were not disclosed.

Under the collaboration, the parties will combine their respective capabilities to advance candidate discovery and optimization. SpiroChem will leverage its drug discovery platform, macrocycle library, and screening engine to lead hit identification and optimization, while ITM will contribute its expertise in radiopharmaceutical development from preclinical research through clinical development. The goal of the collaboration is to identify high-affinity binders and advance the development of a potential first-in-class radiopharmaceutical candidate.

The collaboration targets specific cancer markers in solid tumor indications, with the aim of developing small-molecule targeted agents for cancer types with limited treatment options. The parties stated that the project will explore high-quality chemistry suitable for targeted radionuclide therapy and drive research progress through design, synthesis, and testing.

ITM stated that the collaboration with SpiroChem will bring new drug discovery capabilities and a differentiated technology platform to the company, supporting its continued expansion of the radiopharmaceutical pipeline and exploration of novel biological targets addressing unmet medical needs. ITM currently has 13 radiopharmaceutical product candidates in development, spanning from preclinical research to Phase III clinical trials.

According to public information, ITM focuses on radiopharmaceutical therapy and diagnostics for difficult-to-treat tumors, with operations covering the research, production, and supply of medical radioisotopes, as well as the combination of radioisotopes with targeting molecules to advance precision oncology product development. SpiroChem, headquartered in Basel, Switzerland, is a spin-off of ETH Zurich specializing in complex medicinal chemistry and integrated drug discovery, with technical expertise in the design and optimization of macrocycles, peptides, and other complex molecules.